



Tanvex BioPharma announces proposed public offering of common stock

July 04, 2018

Tanvex BioPharma, Inc. (TWSE: 6541) announced it has commenced an underwritten public offering of 25,000,000 shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Tanvex. KGI is the underwriter and pricing for the offering is set at NTD 85 per share.

Tanvex intends to use the net proceeds from this offering to support the launch of TX-01, and for ongoing manufacturing, development and clinical trial activities related to TX-05 and TX-16.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.